Table 5. Association of genotype with angiographically significant restenosis.
| Gene/Polymorphism | Dominant Model; OR (95% CI) | P | Recessive Mode; OR (95% CI) | P | Log additive model; OR (95% CI) | P |
|---|---|---|---|---|---|---|
| TGFB1 genotype | A/A (ref.) vs. (A/G + G/G) | (A/A + A/G) (ref.) vs. G/G | Per each G allele | |||
| OR unadjusted | 1.99 (0.96–4.10) | 0.05 | 0.88 (0.41–1.90) | 0.75 | 1.25 (0.82–1.91) | 0.30 |
| OR adjusted | 2.27 (1.06–4.87) | 0.03 | 0.94 (0.42–2.08) | 0.87 | 1.35 (0.86–2.10) | 0.19 |
| PDGFB genotype | T/T (ref.) vs. (T/C + C/C) | (T/T + T/C) (ref.) vs. (C/C) | Per each C allele | |||
| OR unadjusted | 0.89 (0.48–1.64) | 0.71 | 1.59 (0.72–3.54) | 0.26 | 1.07 (0.69–1.66) | 0.75 |
| OR adjusted | 0.87 (0.46–1.64) | 0.67 | 1.44 (0.63–3.30) | 0.40 | 1.03 (0.66–1.62) | 0.89 |
| EGF genotype | A/A (ref.) vs. (A/G + G/G) | (A/A + A/G) (ref.) vs. G/G | Per each G allele | |||
| OR unadjusted | 1.09 (0.58–2.05) | 0.80 | 1.08 (0.54–2.18) | 0.83 | 1.06 (0.71–1.57) | 0.78 |
| OR adjusted | 1.02 (0.53–1.97) | 0.94 | 0.94 (0.45–1.95) | 0.86 | 0.99 (0.66–1.49) | 0.95 |
| bFGF genotype | C/C (ref.) vs. (C/G + G/G) | |||||
| OR unadjusted | 1.02 (0.49–2.15) | 0.95 | * | * | * | * |
| OR adjusted | 1.29 (0.59–2.81) | 0.53 | * | * | * | * |
| VEGF-A genotype | A/A (ref.) vs. (A/C + C/C) | (A/A + A/C) vs. C/C | Per each C allele | |||
| OR unadjusted | 0.68 (0.36–1.28) | 0.24 | 0.89 (0.44–1.83) | 0.76 | 0.82 (0.54–1.25) | 0.35 |
| OR adjusted | 0.69 (0.36–1.34) | 0.28 | 0.96 (0.46–2.00) | 0.91 | 0.85 (0.55–1.30) | 0.45 |
* not calculated because of low number of minor homozygotes.
The models were adjusted for clinical variables that reached p value of <0.3 in the comparison of patients with and without significant ISR.
Abbreviations: TGFB1 –transforming growth factor beta 1, PDGFB—platelet-derived growth factor beta polypeptide, EGF–epidermal growth factor, bFGF–basic fibroblast growth factor, VEGF-A–vascular endothelial growth factor A.